Single-cell RNA-seq and TCR-seq of Panc02-Fluc model with vehicle, anti PD1-IL2v, PD1, FAP-IL2v and PD1+FAP-IL2v treatment. Single-cell RNA-seq and TCR-seq of Panc02-Fluc model with vehicle, anti PD1-IL2v, PD1, FAP-IL2v and PD1+FAP-IL2v treatment

Differentiating PD-1 + TCF-1 + stem-like CD8 T cells towards a distinct effector T cell population with enhanced anti-tumor and anti-viral efficacy by delivering an engineered IL-2 variant through PD-1 mediated cis-targeting; Single time point at termination (day 3 after 2nd Ab therapy); Tumor model: Panc02-Fluc pancreatic subcutaneous; Groups 0.5 mg/kg muPD-1-IL2v, 10 mg/kg muPD1, 1.5 mg/kg muFAP-IL2v, 10 mg/kg muPD1 + 1.5 mg/kg muFAP-IL2v, Vehicle; scRNA-seq analysis including feature barcoding and TCR-seq.

通过程序性死亡受体1（PD-1）介导的顺式靶向递送工程化白细胞介素2（IL-2）变体，将PD-1+T细胞因子1（TCF-1）+干细胞样CD8阳性T细胞诱导分化为具有增强抗肿瘤与抗病毒功效的独特效应T细胞亚群；实验仅在终止阶段采集单个时间点样本（第二次抗体治疗后第3天）；肿瘤模型采用Panc02-Fluc胰腺皮下移植瘤模型；实验组设置为：0.5 mg/kg muPD-1-IL2v组、10 mg/kg muPD1组、1.5 mg/kg muFAP-IL2v组、10 mg/kg muPD1联合1.5 mg/kg muFAP-IL2v组以及空白载体（Vehicle）对照组；分析手段包含单细胞RNA测序（single-cell RNA sequencing, scRNA-seq），并同步开展特征条形码标记与T细胞受体测序（TCR-seq）。